Uso de vacuna Valergen DP en la rinitis alérgica

background: allergic rhinitis produced a significant deterioration in the quality of life. sublingual immunotherapy represents a natural way to induce tolerance in the allergic disorder. objective: to assess the efficacy and safety of allergenic extract valergen-dp from mite dermatophagoides pteronyssinus as sublingual therapeutic vaccine in patients with allergic rhinitis. method: a clinical trial, phase ii, double-blind, parallel, randomized, controlled with a placebo group was conducted. vaccines were provided via sublingual in an increasing dose schedule. the treatment had a minimal duration of one year with frequent evaluations. the 40 patients included, two groups of 20 were assigned, previous informed consent. results: it was observed an average decrease in the mean of symptoms, as well as drugs consumption in the active group in relation to the placebo with 156,3 (p=0,000) and 43.5 (p = 0, 000) respectively. values of the mean of skin reactivity declined in the active group not so in the placebo with 2.6 %. only four adverse events were reported, none fatal, representing a 0.2 %. conclusions: sublingual immunotherapy with dermatophagoide pteronyssinus is safe and effective for the treatment of patients with allergic rhinitis.